| | Summary statistic | Overall, N = 86 | Predialysis sK+ at randomization (visit 4, day 1) (mmol/L) | | <5.5, n = 14 | 5.5 to <6.0, n = 37 | 6.0 to <6.5, n = 21 | ≥6.5, n = 14 |
| | Demographics | | Age, years, mean (SD) | 60.3 (13.2) | 53.4 (12.3) | 64.1 (11.1) | 58.2 (14.7) | 60.1 (14.7) | | Age, years, n (%) | | | | | | | 18–50 | 18 (20.9) | 6 (42.9) | 5 (13.5) | 4 (19.0) | 3 (21.4) | | 51–64 | 28 (32.6) | 4 (28.6) | 11 (29.7) | 8 (38.1) | 5 (35.7) | | 65–84 | 39 (45.3) | 4 (28.6) | 21 (56.8) | 8 (38.1) | 6 (42.9) | | ≥85 | 1 (1.2) | 0 (0) | 0 (0) | 1 (4.8) | 0 (0) | | Female sex, n (%) | 36 (41.9) | 3 (21.4) | 15 (40.5) | 11 (52.4) | 7 (50.0) | | Race, n (%) | | White | 43 (50.0) | 5 (35.7) | 18 (48.6) | 11 (52.4) | 9 (64.3) | | Black or African American | 6 (7.0) | 3 (21.4) | 2 (5.4) | 1 (4.8) | 0 (0) | | Asian | 31 (36.0) | 3 (21.4) | 17 (45.9) | 8 (38.1) | 3 (21.4) | | American Indian or Alaska Native | 2 (2.3) | 2 (14.3) | 0 (0) | 0 (0) | 0 (0) | | Other | 4 (4.7) | 1 (7.1) | 0 (0) | 1 (4.8) | 2 (14.3) |
| | Clinical characteristics | | Height, cm, mean (SD) | 165.0 (9.2) | 169.1 (10.1) | 164.3 (7.9) | 164.9 (11.8) | 162.7 (5.9) | | Weight, kg, mean (SD) | 72.7 (16.4) | 75.2 (15.0) | 70.2 (15.3) | 78.7 (20.1) | 68.1 (12.0) | | Body mass index, kg/m2, mean (SD) | 26.7 (5.5) | 26.2 (4.6) | 25.9 (5.3) | 28.9 (6.7) | 25.7 (4.4) | | Predialysis sK+, mmol/L, mean (SD) | 6.0 (0.4) | 5.9 (0.3) | 5.9 (0.4) | 6.0 (0.3) | 6.3 (0.7) | | Serum bicarbonate, mmol/L, mean (SD) | 20.1 (2.4) | 19.3 (1.9) | 20.0 (2.2) | 20.9 (3.3) | 19.8 (1.9) |
| | Dialysis parameters | | Vintage, years, mean (SD) | 7.9 (7.8) | 5.2 (3.9) | 9.7 (8.8) | 7.3 (8.9) | 6.9 (4.8) | | Duration of dialysis session, minutes, mean (SD) | 241.7 (31.9) | 236.1 (41.5) | 245.7 (34.4) | 242.8 (17.8) | 235.1 (31.9) | | Dialysate potassium, mmol/L, mean (SD) | 2.2 (0.5) | 2.1 (0.5) | 2.2 (0.4) | 2.3 (0.5) | 2.4 (0.5) | | Dialysate potassium, mmol/L, n (%) | | 1 | 1 (1.2) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | | 2 | 63 (73.3) | 11 (78.6) | 30 (81.1) | 14 (66.7) | 8 (57.1) | | 3 | 22 (25.6) | 2 (14.3) | 7 (18.9) | 7 (33.3) | 6 (42.9) | | spKt/V, mean (SD) | 1.7 (0.4) | 1.5 (0.2) | 1.7 (0.4) | 1.8 (0.4) | 1.9 (0.3) | | Dialysate flow, mL/min, mean (SD) | 548.0 (131.1) | 583.6 (220.8) | 563.4 (113.1) | 521.9 (98.9) | 511.1 (92.8) | | Prescribed ultrafiltration rate, mL, mean (SD) | 2785.8 (1228.1) | 2426.6 (1665.1) | 2929.8 (1250.4) | 2871.4 (998.1) | 2635.7 (996.6) | | Urea removal rate, %, mean (SD) | 74.3 (5.8) | 71.8 (6.4) | 74.1 (5.2) | 74.1 (6.1) | 75.9 (6.7) |
| | Key medical history, n (%) | | Hypertension | 69 (80.2) | 11 (78.6) | 31 (83.8) | 16 (76.2) | 11 (78.6) | | Dyslipidemia | 14 (16.3) | 2 (14.3) | 5 (13.5) | 5 (23.8) | 2 (14.3) | | Cardiac failure | 4 (4.7) | 0 (0.0) | 3 (8.1) | 0 (0.0) | 1 (7.1) | | Diabetes mellitus | 10 (11.6) | 1 (7.1) | 5 (13.5) | 2 (9.5) | 2 (14.3) | | Type 1 diabetes mellitus | 2 (2.3) | 0 (0.0) | 1 (2.7) | 0 (0.0) | 1 (7.1) | | Type 2 diabetes mellitus | 22 (25.6) | 4 (28.6) | 11 (29.7) | 4 (19.0) | 3 (21.4) |
| | Key allowed concomitant medications, n (%) | | ACE inhibitors | 12 (14.0) | 3 (21.4) | 4 (10.8) | 3 (14.3) | 2 (14.3) | | Angiotensin II antagonists | 23 (26.7) | 2 (14.3) | 16 (43.2) | 3 (14.3) | 2 (14.3) | | Angiotensin II antagonists + calcium channel blockers | 2 (2.3) | 0 (0.0) | 2 (5.4) | 0 (0.0) | 0 (0.0) | | Aldosterone antagonists | 3 (3.5) | 0 (0.0) | 2 (5.4) | 1 (4.8) | 0 (0.0) |
|
|
